Vital status at last follow-up (No. of patients) | |||||
---|---|---|---|---|---|
deceased | living | unknown | |||
262 (54%) | 217 (44%) | 7 (2%) | |||
years to death (years) | |||||
min | median | max | |||
0.02 | 2.43 | 12.67 | |||
Years to last follow-up (years) | |||||
min | median | max | |||
0.02 | 2.44 | 15.01 | |||
Years to tumor recurrence (years) | |||||
min | median | max | |||
0.01 | 1.23 | 9.25 | |||
Age at diagnosis | |||||
min | median | max | |||
27 | 59 | 89 | |||
Site of tumor first recurrence (No. of patients) | |||||
loco-regional | metastasis | unknown | |||
124 (26%) | 118 (24%) | 244 (50%) | |||
Stages (No. of patients) | |||||
1 | 2 | 3 | 4 | unknown | |
14 (3%) | 21 (4 %) | 366 (75%) | 72 (15%) | 13(3%) | |
Grade (No. of patients) | |||||
1 | 2 | 3 | 4 | unknown | |
4(1%) | 57 (12%) | 410 (84%) | 1 (0%) | 14 (3%) | |
Tumor residual disease (No. of patients) | |||||
1-10 mm | 11-20 mm | >20 mm | no macroscopic disease | unknown | |
212 (44%) | 26 (5%) | 79 (16%) | 95 (20%) | 74 (15%) | |
Primary therapy outcome (No. of patients) | |||||
complete response | partial response | progressive disease | stable disease | unknown | |
270 (56%) | 56 (12%) | 36 (7%) | 23 (5%) | 101 (21%) |